The pharmacotherapy of panic disorder

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 4, 2005, Pages 23-27

  Pollack, Mark H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PINDOLOL; PREGABALIN; PROPRANOLOL; SERTRALINE; TIAGABINE; VALPROIC ACID; VENLAFAXINE;

ANXIETY; AVOIDANCE BEHAVIOR; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; ORTHOSTATIC HYPOTENSION; PANIC; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BUPROPION; HUMANS; LONG-TERM CARE; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 18344375473     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Pollack MH, Otto MW, Majcher D, et al. Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Am J Psychiatry 1996;153:376-381
3. Manfro GG, Otto MW, McArdle ET, et al. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord 1996;41:135-139
4. Candilis PJ, McLean RY, Otto MW, et al. Quality of life in patients with panic disorder. J Nerv Ment Dis 1999;187:429-434
5. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community: social morbidity and health care utilization. JAMA 1991;265:742-746
6. Simon GE, VonKorff M. Somatization and psychiatric disorders in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry 1991;148:1494-1500
7. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder: a comparison with primary unipolar depression. Arch Gen Psychiatry 1982;39:701-703
8. Kawachi I, Sparrow D, Vokonas PS, et al. Symptoms of anxiety and risk of coronary heart disease: the Normative Aging Study. Circulation 1994;90:2225-2229
9. Sartorius N, Ustun TB, Costa e Silva JA, et al. An international study of psychological problems in primary care: preliminary report from the World Health Organization Collaborative Project on Psychological Problems in General Health Care. Arch Gen Psychiatry 1993;50:819-824
10. Ormel J, Von Korff M, Ustun TB, et al. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 1994;272:1741-1748
11. Katon W. Panic disorder and somatization: a review of 55 cases. Am J Med 1984;77:101-106
12. Bridges KW, Goldberg DP. Somatic presentation of DSM-III psychiatric disorders in primary care. J Psychsom Res 1985;29:563-569
13. Salvador-Carulla L, Segui J, Fernandez-Cano P, et al. Costs and offset effect in panic disorders. Br J Psychiatry Suppl 1995;27:23-28
14. Middleton HC, Ashby M. Clinical recovery from panic disorder is associated with evidence of changes in cardiovascular regulation. Acta Psychiatr Scand 1995;91:108-113
15. Tucker P, Adamson P, Miranda R Jr, et al. Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol 1997;17:370-376
16. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
17. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016
18. Rapaport MH, Pollack M, Wolkow R, et al. Is placebo response the same as drug response in panic disorder? Am J Psychiatry 2000;157:1014-1016
19. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003;64:1322-1327
20. Pollack MH, Lepola U, Tzanis E, et al. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology; Dec 7-11, 2003; San Juan, Puerto Rico
21. Noyes R Jr, Perry P. Maintenance treatment with antidepressants in panic disorder. J Clin Psychiatry 1990;51(12, suppl A):24-30
22. Emmanuel NP, Lydiard RB, Villareal G. Imipramine in the treatment of social phobia: a double-blind study. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8, 1997; Waikoloa, Hawaii
23. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo controlled trial. J Clin Psychopharmacol 1992;12:251-261
24. den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
25. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997;95:153-160
26. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 1997;58:555-561
27. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
28. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160:1432-1438
29. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 2003;54:1006-1011
30. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-686
31. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276-282
32. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-136
33. Lum M, Fontaine R, Elie R, et al. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 1990;27(suppl 1):164A-165A
34. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988;145:1104-1109
35. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-471
36. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004;65:1219-1222
37. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-249
38. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003;64:1245-1249
39. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983;3:28-31
40. Simon NM, Emmanuel N, Ballenger J, et al. Bupropion sustained release for panic disorder. Psychopharmacol Bull 2003;37:66-72
41. Gastfriend DR, Rosenbaum JF. Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 1989;146:914-916
42. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11
43. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-559
44. Pollack MH, Marzol PC. Panic: course, complications and treatment of panic disorder. J Psychopharmacol 2000;14(suppl 1):S25-S30
45. O'Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of Panic Disorder, 3: outcome at 5 to 6 years. Br J Psychiatry 1996;168:462-469
46. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:318-323
47. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998;18(suppl 2):12S-18S
48. Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 2002;22:294-299
49. Katschnig H, Amering M, Stolk JM, et al. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996;32:149-155
50. Roy-Byrne P, Cowley DS. Clinical approach to treatment-resistant panic. In: Rosenbaum JF, Pollack MH, eds. Panic Disorder and Its Treatment. New York, NY: Marcel Decker; 1998:205-228
51. Simon NM, Safren SA, Otto MW, et al. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 2002;69:201-208
52. Lydiard RB, Steiner M, Burnham D, et al. Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull 1998;34:175-182
53. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 1999;174:213-218
54. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001;104:289-298